Tetra Discovery Partners Initiates Phase 2 Clinical Trial of BPN14770 in Patients with Early Alzheimer’s Disease

Wednesday, May 01, 2019
Image
NIH Default Logo

Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the initiation of a Phase 2 clinical trial (PICASSO AD) of BPN14770 in patients diagnosed with early Alzheimer’s disease (AD).

Was this page helpful?
Form Approved OMB# 0925-0648 Exp. Date 05/31/2021